All In Biotech

Drug Trial Radar · NCT03921775

A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery

A Multicenter, Randomized, Single-blind, Parallel and Control Phase III Trial Evaluating the Efficacy and Safety of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery.

Last checked: Nov 20, 2026Latest source record: May 15, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

330

Actual

Start

May 13, 2019

Primary completion

Dec 30, 2019

Study completion Dec 30, 2019

Sponsor

Sponsor type
Industry
First posted
Apr 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of remimazolam tosilate compared to propofol for general anesthesia during elective surgery.

Conditions

  • Anesthesia for Elective Surgery Patients

Interventions

  • Remimazolam TosilateDrug

    For induction and maintenance of general anesthesia

  • PropofolDrug

    For induction and maintenance of general anesthesia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage(%) of paticipants who experienced successful anesthesia during operation in each groupTime frame: Average of 2 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.